Biblio
CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168-e178.
. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. Transpl Immunol. 2021:101520.
. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.
The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). Biol Blood Marrow Transplant. 2018.
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023.
. EGFR as a potent CAR T target in triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2022.
Impact of COVID-19 in Hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2022.
Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplant Cell Ther. 2021.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analys. Clin Lymphoma Myeloma Leuk. 2023.
Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated Myelodysplastic syndrome: A Systematic Review and Meta-Analysis. Crit Rev Oncol Hematol. 2024:104310.
Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther. 2021.
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leuk Lymphoma. 2024:1-10.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023.
Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study. Bone Marrow Transplant. 2023.
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience. Transpl Immunol. 2024:102039.
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review. Front Oncol. 2024;14:1383730.
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. Hematol Oncol Stem Cell Ther. 2024;17(2):88-94.